SLC5A2 and Hyperkalemia: These proposals are based on the rationale described above and also on the ability of one treatment to enhance the tolerability and safety of another e.g. SGLT2 inhibitors and sacubitril/valsartan reduce the risk of hyperkalemia in patients taking an MRA.